If You Invested $100 In This Stock 5 Years Ago, Here’s How Much You Would Have Today
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.86% on an annualized basis.
This Foreboding Sign Looms Over Insulet’s Chart
If history is any guide, there may be trouble ahead for shares of Insulet (NASDAQ:PODD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Raymond James Maintains Outperform on Insulet, Raises Price Target to $329
Raymond James analyst Jayson Bedford maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $285 to $329.
Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $303
Morgan Stanley analyst David Lewis maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $276 to $303.
10 Biggest Price Target Changes For Friday
Wedbush raised Uber Technologies, Inc. (NYSE: UBER) price target from $51 to $57. Uber shares rose 7.5% to trade at $48.67 on Friday.
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Insulet’s Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
Insulet Corporation (NASDAQ:PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System. Omnipod 5…
Insulet Corporation Announces Co.’s Omnipod 5 Pivotal Study Extension Data Shows Significant Improvements In Glycemic Control With One Year Of Use
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented positive pivotal trial extension phase results for
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)